Topotecan for Irinotecan-Refractory SCLC

Summary

Although the efficacy of topotecan as second-line chemotherapy for SCLC has been consistently demonstrated in phase II/III clinical trials, the choice of irinotecan as first-line therapy prevented use of the evidence-based option. This pilot study will be conducted to determine the activity and safety of topotecan in SCLC patients refractory to first-line therapy with irinotecan and platinum.

Timeline

Start

2004-09

Primary completion

—

Completion

2007-08

Drugs

Indications